Abstract:
|
Regulation of AI-based Software as a Medical Device is slowly growing. There are several challenges around algorithm updates, including the algorithm change protocol (ACP) and the predetermined change control plan (PCCP). Algorithm changes are not expected to fall under one of the traditional approval pathways, e.g., 510(k), De Novo Classification, or a PMA, and the regulatory burden of algorithm changes will be related to risk, i.e., the patient condition and the significance of information provided by the algorithm. Algorithm changes of interest include model performance, algorithm inputs, and the intended use. Drawing from our experience with a recent submission and approval, we highlight several algorithm changes that do and do not require a premarket review. These changes include new model architecture, training with new data, modifications to the modeling input, and expansion to new use cases. We also highlight future challenges, including the concept of Good Machine Learning Practices and real-world performance monitoring.
|